Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm QuanDx Closes Series B Financing

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuanDx announced on Thursday the closing of its Series B financing round raising $1.25 million.

Proceeds will go toward further development of its platform technology and its commercial program in oncology, genetic diseases, and infectious diseases. The Menlo Park, Calif.-based company did not disclose the names of the investors.

Founded in 2010, QuanDx is developing clinical diagnostic assays based on its proprietary Yin-Yang probe technology. According to the company, the probes, made up of two complementary oligonucleotides of different lengths that are labeled, "can specifically detect nucleic acid in a homogeneous format."

QuanDx said that its first commercial product will be its Q-Fusion Leukemia Fusion Gene Screening kit, which uses RT-qPCR to detect 32 fusion genes simultaneously. Other products in the company's pipeline include kits for detecting different numbers of fusion genes in leukemia patients.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.